TOP1 Modulation During Melanoma Progression and in Adaptive Resistance to BRAF and MEK Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors
Pharmacol Res 2021 Nov 01;173(xx)105911, ÉA Oliveira, J Chauhan, JRD Silva, LADC Carvalho, D Dias, DG Carvalho, LRM Watanabe, VW Rebecca, G Mills, Y Lu, ASF da Silva, MEL Consolaro, M Herlyn, PA Possik, CR Goding, SS Maria-EnglerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.